The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Kinetic and Structural Studies on the Interaction of Cholinesterases with the Anti-Alzheimer Drug Rivastigmine,
Open accessAbstract
Rivastigmine, a carbamate inhibitor of acetylcholinesterase, is already in use for treatment of Alzheimer's disease under the trade name of Exelon. Rivastigmine carbamylates Torpedo californica acetylcholinesterase very slowly (k(i) = 2.0 M(-1) min(-1)), whereas the bimolecular rate constant for inhibition of human acetylcholinesterase is >1600-fold higher (k(i) = 3300 M(-1) min(-1)). For human butyrylcholinesterase and for Drosophila melanogaster acetylcholinesterase, carbamylation is even more rapid (k(i) = 9 x 10(4) and 5 x 10(5) M(-1) min(-1), respectively). Spontaneous reactivation of all four conjugates is very slow, with <10% reactivation being observed for the Torpedo enzyme after 48 h. The crystal structure of the conjugate of rivastigmine with Torpedo acetylcholinesterase was determined to 2.2 A resolution. It revealed that the carbamyl moiety is covalently linked to the active-site serine, with the leaving group, (-)-S-3-[1-(dimethylamino)ethyl]phenol, being retained in the "anionic" site. A significant movement of the active-site histidine (H440) away from its normal hydrogen-bonded partner, E327, was observed, resulting in disruption of the catalytic triad. This movement may provide an explanation for the unusually slow kinetics of reactivation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new and rapid colorimetric determination of acetylcholinesterase activity
Ellman, G. L., Courtney, K. D., Andres, V., & Featherstone, R. M. (1961) · Biochemical Pharmacology · doi:10.1016/0006-2952(61)90145-9 · Cited by 27,126
The Pharmacological Basis of Therapeutics
(1976) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/33.4.373a · Cited by 8,209
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
Acetylcholinesterase: Enzyme structure, reaction dynamics, and virtual transition states
Quinn, D. M. (1987) · Chemical Reviews · doi:10.1021/cr00081a005 · Cited by 1,072
Handbuch der Experimentellen Pharmakologie
(1939) · Springer eBooks · doi:10.1007/978-3-642-90793-7 · Cited by 966
Folding and binding cascades: Dynamic landscapes and population shifts
Kumar, S., Ma, B., Tsai, C., Sinha, N., & Nussinov, R. (2000) · Protein Science · doi:10.1110/ps.9.1.10 · Cited by 595
Studies on the relationship between chemical constitution and physiological action
Easson, L. H., & Stedman, E. (1933) · Biochemical Journal · doi:10.1042/bj0271257 · Cited by 451
Harel, M., Quinn, D. M., Nair, H. K., Silman, I., & Sussman, J. L. (1996) · Journal of the American Chemical Society · doi:10.1021/ja952232h · Cited by 369
Self-citationStructure of acetylcholinesterase complexed with (−)‐galanthamine at 2.3 Å resolution
Greenblatt, H. M., Kryger, G., Lewis, T., Silman, I., & Sussman, J. L. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01637-3 · Cited by 310
Self-citationHarel, M., Kryger, G., Rosenberry, T. L., Mallender, W. D., Lewis, T., Fletcher, R. J., Guss, J. M., Silman, I., & Sussman, J. L. (2000) · Protein Science · doi:10.1110/ps.9.6.1063 · Cited by 299
Self-citation
Cited by
Stepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., & Aleo, M. D. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200168d · Cited by 698
Targeting acetylcholinesterase and butyrylcholinesterase in dementia
Lane, R. M., Potkin, S. G., & Enz, A. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005833 · Cited by 654
Self-citationBiochemical mechanisms of drug action: what does it take for success?
Swinney, D. C. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1500 · Cited by 394
Strategies for Discovering and Derisking Covalent, Irreversible Enzyme Inhibitors
Johnson, D. S., Weerapana, E., & Cravatt, B. F. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.21 · Cited by 387
Wilkinson, D. G., Francis, P. T., Schwam, E., & Payne-Parrish, J. (2004) · Drugs & Aging · doi:10.2165/00002512-200421070-00004 · Cited by 365
The pharmacological landscape and therapeutic potential of serine hydrolases
Bachovchin, D. A., & Cravatt, B. F. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3620 · Cited by 308
Long, J. Z., Nomura, D. K., & Cravatt, B. F. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.05.009 · Cited by 303
Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine
Zemek, F., Drtinova, L., Nepovimova, E., Sepsova, V., Korabecny, J., Klimes, J., & Kuca, K. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.914168 · Cited by 299
Acetylcholinesterase: How is structure related to function?
Silman, I., & Sussman, J. L. (2008) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2008.05.035 · Cited by 263
Self-citationRamsay, R., & Tipton, K. (2017) · Molecules · doi:10.3390/molecules22071192 · Cited by 258
Yang, Z.-Z., Zhang, Y.-Q., Wang, Z.-Z., Wu, K., Lou, J.-N., & Qi, X.-R. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.05.009 · Cited by 248
Evaluation of NHS Carbamates as a Potent and Selective Class of Endocannabinoid Hydrolase Inhibitors
Niphakis, M. J., Cognetta, A. B., Chang, J. W., Buczynski, M. W., Parsons, L. H., Byrne, F., Burston, J. J., Chapman, V., & Cravatt, B. F. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400116z · Cited by 157
Shamsi, A., Mohammad, T., Anwar, S., Alajmi, M. F., Hussain, A., Hassan, M. I., Ahmad, F., & Islam, A. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.01.134 · Cited by 73
Vicente-Zurdo, D., Rosales-Conrado, N., León-González, M. E., Brunetti, L., Piemontese, L., Pereira-Santos, A. R., Cardoso, S. M., Madrid, Y., Chaves, S., & Santos, M. A. (2022) · Biomedicines · doi:10.3390/biomedicines10071510 · Cited by 47
“Rivastigmine (trade name Exelon) is a well-known, second-generation carbamate ChE inhibitor drug (approved by the FDA in 2000) that alleviates the symptoms of the disease through the deceleration of its progression [37,38] and presents advantages over first-generation drugs: rapid BBB crossing and low marginal side ef…”
Background
Metadata
- Authors
- Bar-On, P., Millard, C. B., Harel, M., Dvir, H., Enz, A., Sussman, J. L., & Silman, I.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2002-02-19
- Volume
- 41
- Issue
- 11
- Pages
- 3555-3564
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W1988940766
- Cited by
- 328
- References
- 19
- FWCI
- 8.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.